ライフサイエンスコーパス: macitentan

1 vation, revealing the analgesic potential of macitentan.

2 observed survival of the placebo (n=250) and macitentan 10 mg (n=242) groups using a log-rank test an

3 igated the efficacy and safety of M/T FDC vs macitentan 10 mg and vs tadalafil 40 mg monotherapies in

4 ouble-blind period (randomly assigned 1:1 to macitentan 10 mg or placebo once daily) followed by a 12

5 ver 3 years, risk of mortality observed with macitentan 10 mg was 35% lower than predicted mortality

6 e voice/web response system, to receive oral macitentan (10 mg once a day) or placebo.

7 zed (1:1:1) to receive oral doses of 3 mg of macitentan, 10 mg of macitentan, or placebo once daily a

8 on with M/T FDC was significantly greater vs macitentan (29%; geometric mean ratio 0.71; 95% CL: 0.61

9 ndomly assigned to treatment (40 patients to macitentan, 40 patients to placebo).

10 sought to investigate the effects of chronic macitentan, a dual ET-A/ET-B receptor antagonist, on car

11 We assessed the efficacy of macitentan, a new dual endothelin-receptor antagonist, u

12 Among these, compound 17 (macitentan, ACT-064992) emerged as particularly interest

13 tes vasculopathy in systemic sclerosis after macitentan, an endothelin-1 blocker.

14 the two receptors by inhibiting ET(A)R with macitentan, an ET(A)R antagonist approved for treatment

15 HF occurred in 20 (28%) patients assigned to macitentan and 13 (18%) assigned to placebo (hazard rati

16 For instance, macitentan and bosentan from endothelin receptor antagon

17 Macitentan and bosentan were associated with 64% and 56%

18 The combination of macitentan and cisplatinum resulted in the potentiation

19 We demonstrate that combination treatment of macitentan and ET(B)R gene therapy inhibits invasion, bu

20 A fixed-dose combination of the ERA macitentan and PDE5i tadalafil (M/T FDC) in a once-daily

21 Macitentan and tadalafil FDC significantly improved PVR

22 Study to Compare the Efficacy and Safety of Macitentan and Tadalafil Monotherapies With the Correspo

23 macitentan at a once-daily dose of 3 mg, or macitentan at a once-daily dose of 10 mg.

24 hypertension to receive placebo once daily, macitentan at a once-daily dose of 3 mg, or macitentan a

25 nts, urologicals, and antithrombotic agents (macitentan, bosentan, epoprostenol, selexipag, sildenafi

26 ion of the cytotoxic effect, indicating that macitentan can enhance sensitivity to chemotherapy.

27 Macitentan caused LV hypertrophy regression independent

28 In vitro studies showed that macitentan decreased the aldosterone-induced cardiomyocy

29 Although macitentan did not modulate diastolic dysfunction in HFp

30 tive ischemic digital ulcers, treatment with macitentan did not reduce new digital ulcers over 16 wee

31 P=0.01), and the hazard ratio for the 10-mg macitentan dose as compared with placebo was 0.55 (97.5%

32 The hazard ratio for the 3-mg macitentan dose as compared with placebo was 0.70 (97.5%

33 andomly assigned to placebo, 250 to the 3-mg macitentan dose, and 242 to the 10-mg macitentan dose.

34 e 3-mg macitentan dose, and 242 to the 10-mg macitentan dose.

35 These results do not support the use of macitentan for the treatment of digital ulcers in this p

36 r of new digital ulcers was 1.44 in the 3-mg macitentan group (n = 88) and 1.46 in the 10-mg macitent

37 itentan group (n = 88) and 1.46 in the 10-mg macitentan group (n = 88) compared with 1.21 in the plac

38 r patient over 16 weeks was 0.94 in the 3-mg macitentan group (n = 95) and 1.08 in the 10-mg macitent

39 itentan group (n = 95) and 1.08 in the 10-mg macitentan group (n = 97) compared with 0.85 in the plac

40 esistance was 0.63 (95% CI 0.58-0.67) in the macitentan group and 0.98 (95% CI 0.91-1.05) in the plac

41 eriod was peripheral oedema (11 [26%] in the macitentan group and five [12%] in the placebo group).

42 an PVR decreased to 73.0% of baseline in the macitentan group and to 87.2% in the placebo group (geom

43 The most common adverse events in the macitentan group were peripheral oedema (9 [23%] of 40 p

44 Macitentan had no effect on change in NT-proBNP (geometr

45 The endothelin receptor antagonist macitentan has demonstrated long-term efficacy in pulmon

46 Moreover, macitentan improved adverse cardiac remodeling, by reduc

47 d, placebo-controlled MERIT-1 trial assessed macitentan in 80 patients with CTEPH adjudicated as inop

48 a solid rationale for clinical evaluation of macitentan in combination with chemotherapy to overcome

49 , double-blind, multicenter trial (SERENADE [Macitentan in Heart Failure With Preserved Ejection Frac

50 We aimed to evaluate efficacy and safety of macitentan in patients with portopulmonary hypertension.

51 ffects of an endothelin receptor antagonist, macitentan, in patients with HF, left ventricular ejecti

52 Macitentan is beneficial for long-term treatment of pulm

53 n ET receptor antagonist, either bosentan or macitentan, markedly attenuated PD-induced MMT, fibrosis

54 ndomized to single-tablet M/T FDC (n = 108), macitentan (n = 35), or tadalafil (n = 44).

55 2017, 85 patients were randomly assigned to macitentan (n=43) or placebo (n=42).

56 reduced left ventricular ejection fraction, macitentan neither lowered NT-proBNP nor improved HF out

57 y Arterial Hypertension], SERAPHIN [Study of Macitentan on Morbidity and Mortality in Patients with S

58 The effect of macitentan on this end point was observed regardless of

59 t exhibit fluid retention were randomized to macitentan or placebo.

60 e oral doses of 3 mg of macitentan, 10 mg of macitentan, or placebo once daily and stratified accordi

61 II-III patients were randomized to M/T FDC, macitentan, or tadalafil depending on their PAH treatmen

62 n change in NT-proBNP (geometric mean ratio [macitentan/placebo], 1.02 [90% CI, 0.88-1.19]; P=0.79) o

63 treatment with the dual ETAR/ETBR antagonist macitentan prevented core complex formation and restored

64 g the placebo run-in, 60 excluded during the macitentan run-in, and 142 were randomized.

65 tability), followed by a 5-week single-blind macitentan run-in, patients who did not exhibit fluid re

66 Macitentan significantly improved pulmonary vascular res

67 INTERPRETATION: In MERIT-1, macitentan significantly improved PVR in patients with i

68 Macitentan significantly reduced morbidity and mortality

69 lafil, and selexipag) versus initial double (macitentan, tadalafil, and placebo) oral therapy in newl

70 ed phase 3b study, evaluated initial triple (macitentan, tadalafil, and selexipag) versus initial dou

71 verse events more frequently associated with macitentan than with placebo were headache, nasopharyngi

72 verse events more frequently associated with macitentan than with placebo were headache, peripheral e

73 During the double-blind period, 36 (84%) macitentan-treated and 33 (79%) placebo-treated patients

74 More macitentan-treated patients developed fluid retention (1

75 Four (9%) macitentan-treated patients had an adverse event leading

76 In vivo macitentan treatment reduced tumor growth, vascularizati

77 uction in pulmonary vascular resistance with macitentan versus placebo.

78 ce, 0.09 [95% CI, -0.37 to 0.54] for 3 mg of macitentan vs placebo and 0.23 [-0.27 to 0.72] for 10 mg

79 ce, 0.23 [95% CI, -0.35 to 0.82] for 3 mg of macitentan vs placebo and 0.25 [95% CI, -0.34 to 0.84] f

80 nd 0.25 [95% CI, -0.34 to 0.84] for 10 mg of macitentan vs placebo).

81 lacebo and 0.23 [-0.27 to 0.72] for 10 mg of macitentan vs placebo).